Modulation of angiopoietin-like 3 expression
AssigneeIsis Pharmaceuticals, Inc.
InventorsRosanne M. Crooke, Mark J. Graham, Richard Lee, Kenneth W. Dobie
Life of this patent
Estimating the term…
Abstract
Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing plasma lipids, plasma glucose and atherosclerotic plaques in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease or metabolic disease, or a symptom thereof.
Claims16
An antisense compound comprising a modified oligonucleotide 10 to 30 linked nucleosides in length targeted to ANGPTL3, wherein the antisense compound reduces expression of ANGPTL3 by at least 40%.
An assay for identifying an antisense compound that inhibits ANGPTL3 comprising:
- a) contacting cells with an antisense compound comprising a modified oligonucleotide 10 to 30 linked nucleosides in length targeted to ANGPTL3;
- b) measuring an amount of ANGPTL3 produced by the cells contacted by the antisense compound targeting ANGPTL3;
- and
- c) comparing the amount of ANGPTL3 produced from the cells contacted with the antisense compound targeting ANGPTL3 to an amount of ANGPTL3 produced by cells not contacted with the antisense compound targeting ANGPTL3;
- wherein a reduction in ANGPTL3 production by the cells contacted by the antisense compound targeting ANGPTL3 compared to the production of ANGPTL3 produced by cells not contacted by the antisense compound targeting ANGPTL3 identifies the antisense compound that inhibits ANGPTL3.
A kit for decreasing ANGPTL3 wherein the kit comprises:
- a) an antisense compound comprising a modified oligonucleotide 10 to 30 linked nucleosides in length targeted to ANGPTL3, wherein the antisense compound reduces expression of ANGPTL3 by at least 40%, and b) a label.
Dependencies are inferred from the claim text.